MedPath

Relationship Between the VEGF Gene Polymorphism and Cardiometabolic Risk Factors

Completed
Conditions
Polymorphism, Restriction Fragment Length
Interventions
Genetic: gene expression
Registration Number
NCT04077554
Lead Sponsor
Poznan University of Medical Sciences
Brief Summary

The aim of the study is to determine the relationship between VEGF gene expression, VEGF gene polymorphism and serum leptin concentration in the Polish population in people with excessive body weight. In addition, the aim of the study is to look for relationships between the VEGF gene polymorphism and anthropometric and biochemical factors of cardiovascular risk and endothelial dysfunction such as body weight, waist circumference, serum total cholesterol, LDL, HDL, triglycerides, glucose and the occurrence of cardiovascular diseases in the family of a patient with excessive body weight in the Polish population.

Detailed Description

400 people (250 - study group; 150 control group) were subjected to subjective and objective action. Information on the occurrence of diseases and cardiovascular risk in the participant and his family was collected from research studies. Anthropometric parameters were measured (body weight, height, BMI, waist circumference, neck circumference) as well as blood pressure and pulse measurement. In addition, fasting venous blood was collected and secured. In venous blood currently marked with the following concentration: glucose, required cholesterol, LDL cholesterol, HDL cholesterol and triglycerides. In addition, a method of salting out and protecting DNA was developed from blood.

Furthermore the polymorphisms of VEGF genes (in positions: -2578 and -634) using the HMR (High Resolution Melt) method was determined.

Also VEGF and leptin by ELISA was determined. After obtaining the results of comparative analysis of the correlation between the occurrence of VEGF gene polymorphisms, serum levels of leptin and VEGF, and anthropometric and biochemical parameters of cardiovascular risk.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
400
Inclusion Criteria
  • informed consent in writing
  • stable body mass (+/- 1 kg)
  • excessive body mass (BMI ≥ 25 kg/m2- study group)
  • proper body mass (BMI < 25 kg/m2- control group)
Exclusion Criteria
  • age <18 years
  • secondary obesity
  • pregnancy, lactation
  • other conditions that in the opinion of researchers may pose any risk to the patient during the study.

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
Control groupgene expressionwomen and men with proper body mass
Study groupgene expressionwomen and men with excess body mass
Primary Outcome Measures
NameTimeMethod
VEGF gene expressionthrough study completion, an average of 1 year

VEGF gene expression

VEGF gene polymorphismthrough study completion, an average of 1 year

VEGF gene polymorphism

serum leptin concentrationthrough study completion, an average of 1 year

serum leptin concentration

Secondary Outcome Measures
NameTimeMethod
Body mass (BM)through study completion, an average of 1 year

Body mass

Waist circumference (WC)through study completion, an average of 1 year

Waist circumference

low density lipoprotein (LDL)through study completion, an average of 1 year

Blood concentration of low density lipoprotein

total cholesterol (TCH)through study completion, an average of 1 year

Blood concentration of total cholesterol

high density lipoprotein (HDL)through study completion, an average of 1 year

Blood concentration of high density lipoprotein

triglyceridesthrough study completion, an average of 1 year

Blood concentration of triglycerides

glucosethrough study completion, an average of 1 year

Blood concentration of glucose

Trial Locations

Locations (1)

Department of Treatment of Obesity, Metabolic Disorders and Clinical Dietetics, Poznan University of Medical Sciences

🇵🇱

Poznan, Wielkopolska, Poland

© Copyright 2025. All Rights Reserved by MedPath